IRIS UniCatt

Lucchini, Matteo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.752
EU - Europa 2.311
AS - Asia 2.187
SA - Sud America 473
AF - Africa 91
OC - Oceania 9
Continente sconosciuto - Info sul continente non disponibili 2
Totale 7.825
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.683
SG - Singapore 1.075
DE - Germania 869
CN - Cina 456
BR - Brasile 394
SE - Svezia 351
IT - Italia 320
VN - Vietnam 181
FR - Francia 175
FI - Finlandia 119
GB - Regno Unito 109
IE - Irlanda 100
ID - Indonesia 78
IN - India 74
JP - Giappone 62
RU - Federazione Russa 51
HK - Hong Kong 46
UA - Ucraina 46
BD - Bangladesh 43
CA - Canada 33
IQ - Iraq 33
PL - Polonia 30
AR - Argentina 29
ZA - Sudafrica 29
CI - Costa d'Avorio 27
NL - Olanda 27
KR - Corea 25
TR - Turchia 24
AT - Austria 20
MX - Messico 17
BE - Belgio 15
EC - Ecuador 13
PK - Pakistan 13
ES - Italia 12
SA - Arabia Saudita 11
CO - Colombia 9
MA - Marocco 9
VE - Venezuela 8
CH - Svizzera 7
JO - Giordania 7
KE - Kenya 7
RO - Romania 7
AE - Emirati Arabi Uniti 6
CL - Cile 6
IL - Israele 6
TN - Tunisia 6
AU - Australia 5
IR - Iran 5
LT - Lituania 5
RS - Serbia 5
UZ - Uzbekistan 5
DK - Danimarca 4
DO - Repubblica Dominicana 4
HU - Ungheria 4
JM - Giamaica 4
KZ - Kazakistan 4
NO - Norvegia 4
NP - Nepal 4
NZ - Nuova Zelanda 4
PS - Palestinian Territory 4
PT - Portogallo 4
PY - Paraguay 4
SN - Senegal 4
BH - Bahrain 3
BO - Bolivia 3
BY - Bielorussia 3
CR - Costa Rica 3
CU - Cuba 3
CZ - Repubblica Ceca 3
DZ - Algeria 3
GR - Grecia 3
MD - Moldavia 3
NI - Nicaragua 3
PE - Perù 3
PH - Filippine 3
SK - Slovacchia (Repubblica Slovacca) 3
UY - Uruguay 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AL - Albania 2
AZ - Azerbaigian 2
BN - Brunei Darussalam 2
EE - Estonia 2
ET - Etiopia 2
KH - Cambogia 2
MK - Macedonia 2
MT - Malta 2
MY - Malesia 2
OM - Oman 2
TH - Thailandia 2
AM - Armenia 1
BA - Bosnia-Erzegovina 1
CG - Congo 1
CY - Cipro 1
EG - Egitto 1
GF - Guiana Francese 1
HR - Croazia 1
HT - Haiti 1
KG - Kirghizistan 1
LB - Libano 1
LU - Lussemburgo 1
Totale 7.818
Salva come PNG Salva come JPEG
Città #
Singapore 625
Chandler 418
Frankfurt am Main 358
San Jose 341
Ashburn 281
Munich 132
Beijing 121
New York 101
Dublin 100
Los Angeles 87
Helsinki 73
Jakarta 67
Lauterbourg 65
Ho Chi Minh City 64
Rome 61
Tokyo 58
Chicago 56
San Mateo 55
Hefei 54
Hanoi 47
Boston 46
São Paulo 41
Hong Kong 40
Princeton 37
Wilmington 37
Milan 30
Nürnberg 30
Dallas 29
Moscow 28
Abidjan 27
Buffalo 27
The Dalles 26
Ann Arbor 25
Redmond 22
Seoul 22
Warsaw 22
Jacksonville 20
Santa Clara 20
Seattle 20
Turku 20
London 19
Salt Lake City 19
Johannesburg 18
Nanjing 18
Atlanta 17
Cattolica 17
Houston 17
Tukwila 17
North Bergen 16
Nuremberg 16
Rio de Janeiro 16
Fairfield 15
Kent 15
Paris 15
Baghdad 14
Brooklyn 14
Council Bluffs 14
Marseille 14
Pune 14
Bremen 12
Chennai 12
Boardman 11
Lappeenranta 11
Montreal 11
Orem 11
Düsseldorf 10
Norwalk 10
Phoenix 10
Amsterdam 9
Brussels 9
Denver 9
Falkenstein 9
Guangzhou 9
Poplar 9
Shanghai 9
Vienna 9
Ankara 8
Bexley 8
Lawrence 8
Woodbridge 8
Amman 7
Belo Horizonte 7
Columbus 7
Dearborn 7
Florence 7
Haiphong 7
Hyderabad 7
Las Vegas 7
Portsmouth 7
Redwood City 7
Andover 6
Elk Grove Village 6
Istanbul 6
Jyväskylä 6
Leawood 6
Mexico City 6
Nairobi 6
Porto Alegre 6
Tampa 6
Tianjin 6
Totale 4.370
Salva come PNG Salva come JPEG
Nome #
Mutations in the 3' untranslated region of FUS causing FUS overexpression are associated with amyotrophic lateral sclerosis 317
Upper body involvement in GNE myopathy assessed by muscle imaging 265
Primary fibroblasts cultures reveal TDP-43 abnormalities in amyotrophic lateral sclerosis patients with and without SOD1 mutations 250
Novel missense variants associated with GNE myopathy 244
An Italian Neurology Outpatient Clinic Facing SARS-CoV-2 Pandemic: Data From 2,167 Patients 174
Serum-Circulating microRNAs in Sporadic Inclusion Body Myositis 164
Alemtuzumab-induced lung injury in multiple sclerosis: Learning from adversity in three patients 163
Prognostic factors after treatment for iterative thymoma recurrences: A multicentric experience 157
New onset of Susac syndrome after mRNA COVID-19 vaccine: a case report 149
Alemtuzumab-induced lung injury in multiple sclerosis: Learning from adversity in three patients 148
A TLR/CD44 axis regulates T cell trafficking in experimental and human multiple sclerosis 147
Wash-out duration and lymphocyte count in switching from fingolimod to ofatumumab: A case report and literature review 147
An Italian Neurology Outpatient Clinic Facing SARS-CoV-2 Pandemic: Data From 2,167 Patients 142
Disease Reactivation after Fingolimod Discontinuation in Pregnant Multiple Sclerosis Patients 142
Mutations in the 3' untranslated region of FUS causing FUS overexpression are associated with amyotrophic lateral sclerosis 141
Predictors of lymphocyte count recovery after dimethyl fumarate-induced lymphopenia in people with multiple sclerosis 140
The Expanding Role of the Infectious Disease Expert in the Context of the MS Centre 140
Long-term Follow-up and Muscle Imaging Findings in Brachio-Cervical Inflammatory Myopathy 136
Novel SEC61G-EGFR fusion gene in pediatric ependymomas discovered by clonal expansion of stem cells in absence of exogenous mitogens 135
A pilot study of lncRNAs expression profile in serum of progressive multiple sclerosis patients 125
Expression Profile of Long Non-Coding RNAs in Serum of Patients with Multiple Sclerosis. 123
Defining the disease course of TNFα blockers-associated Multiple Sclerosis 123
Dominus effect: challenging complications of alemtuzumab-related thyroid autoimmunity 122
Liposome-based nanoparticles impact on regulatory and effector phenotypes of macrophages and T cells in multiple Sclerosis patients 118
Lower urinary tract disorders in multiple sclerosis patients: prevalence, clinical features, and response to treatments 118
The Disease-Modifying Therapies of Relapsing-Remitting Multiple Sclerosis and Liver Injury: A Narrative Review 118
Liposome-based nanoparticles impact on regulatory and effector phenotypes of macrophages and T cells in multiple Sclerosis patients 117
A pilot study of lncRNAs expression profile in serum of progressive multiple sclerosis patients 117
CSF CXCL13 and Chitinase 3-like-1 Levels Predict Disease Course in Relapsing Multiple Sclerosis 114
Severe dyspnoea with alteration of the diffusion capacity of the lung associated with fingolimod treatment 114
A unique case of multiphasic ADEM or what else? 114
Muscle involvement in myasthenia gravis: Expanding the clinical spectrum of myasthenia-myositis association from a large cohort of patients 114
Oculopharyngeal muscular dystrophy: Clinical and neurophysiological features 113
Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis 113
Anti-cN1A Antibodies Are Associated with More Severe Dysphagia in Sporadic Inclusion Body Myositis 113
Ixekizumab exposure associated with myelitis: A case report and a literature review 112
Is serological response to SARS-CoV-2 preserved in MS patients on ocrelizumab treatment? A case report 111
The predictive value of CSF multiple assay in multiple sclerosis: A single center experience 106
Liver injury after pulsed methylprednisolone therapy in multiple sclerosis patients 105
Fingolimod vs dimethyl fumarate in multiple sclerosis 103
Immunogenicity and safety of mRNA COVID-19 vaccines in people with multiple sclerosis treated with different disease-modifying therapies 96
COVID-19 presenting as a non-arteritic anterior ischemic optic neuropathy 95
Cyclophosphamide in highly aggressive Marburg-like multiple sclerosis 95
Neurosarcoidosis presenting as longitudinally extensive myelitis: Diagnostic assessment, differential diagnosis, and therapeutic approach 94
Exit strategies for “needle fatigue” in multiple sclerosis: a propensity score-matched comparison study 93
Safety and Efficacy of Dimethyl Fumarate in Multiple Sclerosis: An Italian, Multicenter, Real-World Study 92
Exit Strategies in Natalizumab-Treated RRMS at High Risk of Progressive Multifocal Leukoencephalopathy: a Multicentre Comparison Study 92
Assessing treatment response to oral drugs for multiple sclerosis in real-world setting: a MAGNIMS Study 87
NEDA-3 achievement in early highly active relapsing remitting multiple sclerosis patients treated with Ocrelizumab or Natalizumab 87
Long-term Follow-up and Muscle Imaging Findings in Brachio-Cervical Inflammatory Myopathy 86
Current Status of Oral Disease-Modifying Treatment Effects on Cognitive Outcomes in Multiple Sclerosis: A Scoping Review 84
Estimating the impact of COVID-19 pandemic on services provided by Italian Neuromuscular Centers: an Italian Association of Myology survey of the acute phase 84
Multiple Sclerosis Onset before and after COVID-19 Vaccination: Can HLA Haplotype Be Determinant? 82
Tumefactive Demyelinating Lesion Around a Developmental Venous Anomaly: A Rare Association 82
Influence of Previous Disease-Modifying Drug Exposure on T-Lymphocyte Dynamic in Patients With Multiple Sclerosis Treated With Ocrelizumab 80
New onset of Susac syndrome after mRNA COVID-19 vaccine: a case report 79
COVID-19 outbreak in Italy: an opportunity to evaluate extended interval dosing of ocrelizumab in MS patients 78
Maternal and fetal outcomes in an Italian multicentric cohort of women with multiple sclerosis exposed to dimethyl fumarate during pregnancy 77
Muscle biopsy features of idiopathic inflammatory myopathies and differential diagnosis 77
Sativex® effects on promoter methylation and on CNR1/CNR2 expression in peripheral blood mononuclear cells of progressive multiple sclerosis patients 77
Transient hair loss during treatment with dimethyl-fumarate for multiple sclerosis 75
SARS-CoV-2 serology after COVID-19 in multiple sclerosis: An international cohort study 74
Shift of multiple sclerosis onset towards older age 74
Signs and symptoms of COVID-19 in patients with multiple sclerosis 73
The predictive value of CSF multiple assay in multiple sclerosis: A single center experience 68
Dimethyl fumarate vs Teriflunomide: an Italian time-to-event data analysis 67
IgE-mediated allergic reactions to ocrelizumab in multiple sclerosis: A retrospective cohort study 34
Real-world experience with cladribine tablets in people with multiple sclerosis: effectiveness data from a multicenter Italian study 30
Paramagnetic Rim Lesions in Highly Active Multiple Sclerosis at the Time of Disease Diagnosis: Prevalence Data and Clinical Implications 14
Totale 7.940
Salva come PNG Salva come JPEG
Categoria #
all - tutte 34.653
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 34.653
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202115 0 0 0 0 0 0 0 0 0 0 0 15
2021/2022476 42 19 8 61 8 15 6 76 32 26 78 105
2022/20231.111 131 139 77 167 69 136 57 104 140 25 46 20
2023/2024636 23 146 26 37 18 110 44 52 10 21 68 81
2024/20251.405 29 37 110 64 64 92 98 68 180 123 335 205
2025/20263.558 464 74 205 375 595 497 553 172 245 210 135 33
Totale 7.940